Although the latest liver cancer guidelines have not yet identified the role of micro-satellite instability (MSI), mismatch repair (MMR), tumor mutation burden (TMB), or programmed death ligated 1(PD-L1) in HCC [20], partial immune checkpoint suppression has demonstrated clinical benefit. This evidence concerns the gene CD274 and neoplasm.